Monday, October 7, 2013

Aspocid – C


Aspocid – C

Each effervescent tablet contains: Acetylsalicylic acid 500 mg Ascorbic acid 250 mg


Company Name
CID

Therapeutic Group
NON-NARCOTIC ANALGESICS

Pharmaceutical form
Effervescent tablets

Package
A carton box containing 12 effervescent tablets, in aluminum tube .

Indications
Symptomatic relief of common cold and influenza .

Warning & Precautions
* Aspocid-C should be used cautiously in the following cases: • Elderly. • Asthmatic patients. • Renal or hepatic impairment. • Glucose-6- phosphate dehydrogenase deficiency. • Children under 12 years old. • Patients prone to recurrent renal calculi. * All NSAIDs are contra-indicated in Pregnancy especially in last trimester (unless potential benefits overweigh risks). * It is contra-indicated during lactation to avoid risk of Reye's syndrome in infants , maximum 4 gm daily of acetyl salicylic acid .

Product Type
human

Dosage
1-2 tablets to be taken in half a glass of water. This dose may be repeated every ( 4 - 6 ) hours if needed, maximum 4 gm daily of acetyl salicylic acid .

Adverse Reactions
Generally mild and infrequent including: • GIT irritation (can be reduced by taking drug after food ). • Skin and bronchospastic reactions in patients who have hypersensitivity toNSAIDs. • Increased bleeding time.

Contra Indications
- Breast-feeding . - Gastro–intestinal ulceration . - Hemophilia - Gout . - History of hypersensitivity to aspirin and other NSAIDs. - Bronchial asthma .

Drug Interactions
• Anticoagulants or other Antiplatelet drugs: increased risk of bleeding. • Corticosteroids: increased risk of gastrointestinal bleeding and ulceration. • Spironolactone: reduced diuretic effect. • Acetazolamide: reduced excretion of acetazolamide (increased risk of toxicity). • Acidification of urine of vitamin C may cause precipitation of urate or oxalate stones.


5 EgyDrug Index: Aspocid – C Aspocid – C Each effervescent tablet contains: Acetylsalicylic acid 500 mg Ascorbic acid 250 mg Company Name CID Therapeutic Group...

No comments:

Post a Comment